Dexcom

Profile narrative

Dexcom Inc. develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for people with diabetes and for clinical use. Its core product line includes the G6 and G7 sensor platforms, which provide real-time glucose readings transmitted to smart devices or dedicated receivers without routine fingersticks. The company sells directly to consumers through pharmacy and durable medical equipment channels, and it partners with insulin pump manufacturers such as Tandem Diabetes Care and Insulet to enable automated insulin delivery systems. Dexcom's devices are cleared by the U.S. Food and Drug Administration and carry CE marking for the European Economic Area, with additional regulatory authorizations in Canada, Australia, Japan, and other markets. The company operates globally, with commercial presence across North America, Europe, Asia-Pacific, and the Middle East, serving both type 1 and type 2 diabetes populations as well as gestational diabetes patients.

Headquartered in San Diego, California, Dexcom is a publicly traded corporation listed on the Nasdaq under the symbol DXCM and is a component of the S&P 500 index. The organization maintains manufacturing facilities in San Diego and Mesa, Arizona, and has expanded its operational footprint with a distribution center in Kentucky and international subsidiaries supporting sales, regulatory affairs, and customer support. Its distinguishing attributes include a focused specialization on CGM technology rather than a diversified medical device portfolio, a direct-to-consumer digital engagement model that includes data-sharing applications and cloud-based analytics, and a clinical evidence base built on pivotal trials that supported reimbursement decisions by major public and private payers. The company's regulatory strategy has emphasized interoperability designations, allowing its sensors to integrate with multiple automated insulin dosing platforms and digital health applications.

In October 2026, a class-action complaint was filed alleging that Dexcom suffered a cybersecurity intrusion between October 1 and October 5, 2026, during which threat actors identified as ShinyHunters accessed and exfiltrated personal and health information belonging to consumers and employees. The plaintiffs claim the group posted Dexcom's name and a countdown timer on a dark-web leak site, signaling an intent to publish or sell the compromised data. The litigation asserts causes of action including negligence, breach of implied contract, and violations of state consumer protection and data breach notification statutes. Dexcom has not publicly confirmed the scope or root cause of the alleged incident as of the filing date, and the matter remains pending in federal court.

Incidents

0 incidents linked to this organisation.